» Articles » PMID: 29238067

Alternative NHEJ Pathway Proteins As Components of MYCN Oncogenic Activity in Human Neural Crest Stem Cell Differentiation: Implications for Neuroblastoma Initiation

Overview
Journal Cell Death Dis
Date 2017 Dec 15
PMID 29238067
Citations 18
Authors
Affiliations
Soon will be listed here.
Abstract

Neuroblastoma is a cancer of neural crest stem cell (NCSC) lineage. Signaling pathways that regulate NCSC differentiation have been implicated in neuroblastoma tumorigenesis. This is exemplified by MYCN oncogene targets that balance proliferation, differentiation, and cell death similarly in normal NCSC and in high-risk neuroblastoma. Our previous work discovered a survival mechanism by which MYCN-amplified neuroblastoma circumvents cell death by upregulating components of the error-prone non-canonical alternative nonhomologous end-joining (alt-NHEJ) DNA repair pathway. Similar to proliferating stem cells, high-risk neuroblastoma cells have enhanced DNA repair capacity, overcoming DNA damage with higher repair efficiency than somatic cells. Adequate DNA maintenance is required for lineage protection as stem cells proliferate and during tumor progression to overcome oncogene-induced replication stress. On this basis, we hypothesized that alt-NHEJ overexpression in neuroblastoma is a cancer cell survival mechanism that originates from DNA repair systems of NCSC, the presumed progenitor cell of origin. A human NCSC model was generated in which inducible MYCN triggered an immortalized phenotype capable of forming metastatic neuroectodermal tumors in mice, resembling human neuroblastoma. Critical alt-NHEJ components (DNA Ligase III, DNA Ligase I, and Poly [ADP-ribose polymerase 1]) were highly expressed in normal early NCSC, and decreased as cells became terminally differentiated. Constitutive MYCN expression maintained high alt-NHEJ protein expression, preserving the expression pattern of the immature neural phenotype. siRNA knockdown of alt-NHEJ components reversed MYCN effects on NCSC proliferation, invasion, and migration. DNA Ligase III, Ligase I, and PARP1 silencing significantly decreased neuroblastoma markers expression (TH, Phox2b, and TRKB). These results utilized the first human NCSC model of neuroblastoma to uncover an important link between MYCN and alt-NHEJ expression in developmental tumor initiation, setting precedence to investigate alt-NHEJ repair mechanics in neuroblastoma DNA maintenance.

Citing Articles

Comparison of human pluripotent stem cell differentiation protocols to generate neuroblastoma tumors.

Cheng B, Fang W, Pastor S, March A, Porras T, Wu H Sci Rep. 2024; 14(1):23050.

PMID: 39367051 PMC: 11452544. DOI: 10.1038/s41598-024-73947-y.


Pediatric Tumors as Disorders of Development: The Case for In Vitro Modeling Based on Human Stem Cells.

Clairmont C, Gell J, Lau C Cancer Control. 2024; 31:10732748241270564.

PMID: 39118322 PMC: 11311176. DOI: 10.1177/10732748241270564.


ALK upregulates POSTN and WNT signaling to drive neuroblastoma.

Huang M, Fang W, Farrel A, Li L, Chronopoulos A, Nasholm N Cell Rep. 2024; 43(3):113927.

PMID: 38451815 PMC: 11101011. DOI: 10.1016/j.celrep.2024.113927.


BARD1 germline variants induce haploinsufficiency and DNA repair defects in neuroblastoma.

Randall M, Egolf L, Vaksman Z, Samanta M, Tsang M, Groff D J Natl Cancer Inst. 2023; 116(1):138-148.

PMID: 37688570 PMC: 10777668. DOI: 10.1093/jnci/djad182.


Genomic Breakpoint Characterization and Transcriptome Analysis of Metastatic, Recurrent Desmoplastic Small Round Cell Tumor.

Magrath J, Flinchum D, Hartono A, Goldberg I, Espinosa-Cotton M, Moroz K Sarcoma. 2023; 2023:6686702.

PMID: 37457440 PMC: 10344636. DOI: 10.1155/2023/6686702.


References
1.
Brodeur G, Seeger R, Schwab M, Varmus H, Bishop J . Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage. Science. 1984; 224(4653):1121-4. DOI: 10.1126/science.6719137. View

2.
Hogarty M . The requirement for evasion of programmed cell death in neuroblastomas with MYCN amplification. Cancer Lett. 2003; 197(1-2):173-9. DOI: 10.1016/s0304-3835(03)00103-4. View

3.
Sallmyr A, Tomkinson A, Rassool F . Up-regulation of WRN and DNA ligase IIIalpha in chronic myeloid leukemia: consequences for the repair of DNA double-strand breaks. Blood. 2008; 112(4):1413-23. PMC: 2967309. DOI: 10.1182/blood-2007-07-104257. View

4.
Tobin L, Robert C, Rapoport A, Gojo I, Baer M, Tomkinson A . Targeting abnormal DNA double-strand break repair in tyrosine kinase inhibitor-resistant chronic myeloid leukemias. Oncogene. 2012; 32(14):1784-93. PMC: 3752989. DOI: 10.1038/onc.2012.203. View

5.
Orii K, Lee Y, Kondo N, McKinnon P . Selective utilization of nonhomologous end-joining and homologous recombination DNA repair pathways during nervous system development. Proc Natl Acad Sci U S A. 2006; 103(26):10017-22. PMC: 1502498. DOI: 10.1073/pnas.0602436103. View